UroGen Pharma (URGN) Total Non-Current Liabilities (2019 - 2026)

UroGen Pharma (URGN) has 8 years of Total Non-Current Liabilities data on file, last reported at $374.0 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 28.85% year-over-year to $374.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $374.0 million (up 28.85% YoY) and the FY2025 annual result came in at $302.0 million, up 3.89% from the prior year.
• Total Non-Current Liabilities improved to $374.0 million in Q1 2026, from $302.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $374.0 million in Q1 2026 to a low of $179.9 million in Q1 2022.
• A 5-year average of $253.9 million and a median of $240.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 888.39% — and 2025, when it advanced 3.89%.
• Tracing URGN's Total Non-Current Liabilities over 5 years: stood at $222.0 million in 2022, then gained by 8.27% to $240.3 million in 2023, then climbed by 20.97% to $290.7 million in 2024, then gained by 3.89% to $302.0 million in 2025, then increased by 23.84% to $374.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $374.0 million (Q1 2026), $302.0 million (Q4 2025), and $296.7 million (Q3 2025), per Business Quant data.